Email

u251513@bcm.edu

Positions

Associate Professor / Director of Cardiac Regeneration

Surgery
Cardiothoracic Surgery
Baylor College of Medicine
Houston, Texas United States

Associate Professor

Medicine
University of Louisville
Louisville, Kentucky United States

Scientist II

Gene Therapy
Tenaya Therapeutics
San Francisco, California United States

Addresses

McNair Campus (MCHP) (Lab)

Room: MCHP-A06.182
Houston, TX 77030
United States

McNair Campus (MCHP) (Office)

Room: MCHP-A06.182
Houston, TX 77030
United States

Education

Postdoctoral Training at Gladstone Institute

10/2017 - San Francisco, California United States

PhD from University of Manchester

05/2008 - Manchester, United Kingdom

MSc from Zagazig University

03/2003 - Zagazig

PharmD from Zagazig University

05/1999 - Zagazig, Egypt

Professional Interests

• Culturing human heart slices for drug discovery
• Regenerate the heart

Professional Statement

Tamer M. Mohamed, Ph.D., M.Sc., has broad expertise in molecular cardiology and drug screening in addition to cardiac regeneration and epigenetics. During his research endeavors, he studied novel mechanisms and therapies for cardiac hypertrophy and heart failure.

His research had a major impact on two approaches for endogenous heart repair: direct cardiac reprogramming and inducing cardiomyocyte proliferation. Both approaches were highly successful.

The direct reprogramming approach was the nucleus for an emerging start-up (Tenaya Therapeutics) where he was the first scientist recruited to the company to lead the efforts of direct cardiac reprogramming.

Due to the quick success of Tenaya, which IPO in August 2021 to start clinical trials, the research and development section ended very soon and now the major focus is on scaling up viral manufacturing and filing IND which is away from his interest. Therefore, he decided to go back to academia to initiate new discovery programs for heart failure therapy mainly focusing on understanding the regulation of cardiomyocyte proliferation (Abouleisa et al., Circulation, 2022, and Mohamed et al., Cell, 2018).

Most recently, his laboratory established a novel system for long-term culture of human and pig heart slices and efficiently demonstrated the efficacy of new cardiac regenerative therapies in such pre-clinical models (Ou et al., Circulation Research, 2019). This technology has opened a new avenue of research to explore pathophysiological mechanisms and toxicities in primary pig and human heart tissues.

Websites

Selected Publications

• "Regulation of Cell Cycle to Stimulate Adult Cardiomyocyte Proliferation and Cardiac Regeneration." ; Pubmed PMID: 29502971
• "Physiological Biomimetic Culture System for Pig and Human Heart Slices." ; Pubmed PMID: 31310161
• "Heart slice culture system reliably demonstrates clinical drug-related cardiotoxicity." ; Pubmed PMID: 32877659
• "Chemical Enhancement of In Vitro and In Vivo Direct Cardiac Reprogramming." ; Pubmed PMID: 27834668

Funding

Transient expression of the cell cycle factors to treat ischemic heart failure

Grant funding from NIH

An Innovative Therapeutic Approach to Treat Cardiomyopathy

Department of Defence

Model evaluation and evaluating the efficacy of compounds in in vitro cultured human heart tissue slices

Merck

Physiologically relevant cardiac tissue culture model for drug testing and disease modeling

NIH

Intellectual Property

Method Patent (Approved)

Method Patent (Approved)

Method Patent (Pending)

Method Patent (Pending)

Languages

Arabic